Alpha-synuclein seeding models
Recapitulate the key structural features and spreading of alpha-synuclein aggregates found in the brain of Parkinson’s disease and other synucleinopathy patients
Alpha-synuclein (α-syn) inclusions are the main histopathological hallmark correlating with clinical symptoms of not only PD, but also other synucleinopathies such as dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA). In line, the development and spread of α-syn aggregates plays a key role in the disease pathophysiology.
Take advantage of InnoSer’s expertise in modelling α-syn pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience with modelling α-syn pathology in vivo and are happy to help guide your decision on study design fit for your current research goals.
Alpha-synuclein seeding models that InnoSer offers:
- α-syn aggregates can be injected in both wild-type (WT) or transgenic mice.
- Both recombinant and patient-derived seeds are available.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments in the following battery of cognitive behavioural tests:
- Immunohistochemistry (e.g., phospho-α-syn, neurodegeneration)
- Immunofluorescence (e.g., α-syn aggregates, neuroinflammation)
Related Parkinson’s Disease model options
MPTP Induced PD Models
Transgenic Alpha-Synuclein Models
Seeding Alpha-Synuclein Models
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know